Aminex Therapeutics, Inc.

Aminex Therapeutics, Inc. is dedicated to developing innovative immuno-oncology therapies that enhance the immune system's ability to fight solid tumors, focusing on cutting-edge treatments and therapeutic advancements. Founded in 2009 in Kirkland, US, Aminex Therapeutics specializes in immuno-oncology, particularly through its proprietary therapies. The company raised USD 4.

000 mn in Series A funding in November 2015 from individual and unspecified investors, with the total amount raised now standing at USD 4. 000 mn. Jim Skaggs serves as CEO, while Mark Burns is noted as the founder. Aminex Therapeutics specializes in the development of innovative immuno-oncology therapies aimed at enhancing the immune system's capacity to combat solid tumors.

The company's primary product is a proprietary oral small molecule therapy that combines AMXT 1501, a patented polyamine uptake inhibitor, with DiFluoroMethylOrnithine (DFMO, eflornithine), an established polyamine synthesis inhibitor. This dual-action approach effectively reduces the levels of polyamines, which are prevalent in cancer cells and the tumor microenvironment, thereby counteracting immune system suppression. The target end-users for these products include oncologists and healthcare providers treating patients with various solid tumor cancers. Aminex Therapeutics aims to penetrate international markets, focusing on regions with high oncological needs, although specific geographic markets have not been disclosed.

Aminex Therapeutics generates revenue through the commercialization of its immuno-oncology therapies, with a business model centered on partnerships and collaborations with healthcare institutions and pharmaceutical companies. These transactions typically involve agreements for the distribution of their flagship product, which is geared towards hospitals and specialized medical practices treating cancer patients. Pricing plans for their therapies are structured to accommodate various healthcare settings, allowing for flexibility in purchasing based on the needs of the institutions. While specific pricing details are not publicly available, the integration of AMXT 1501 and DFMO is expected to provide value-driven solutions that meet the demands of the oncology market.

The company is focused on building a strong client base that includes medical professionals and institutions dedicated to advancing cancer treatment. Aminex Therapeutics is strategizing for future growth by designing and launching new products aimed at enhancing treatment options in immuno-oncology. The company aims to expand into additional international markets, particularly those with pressing oncological needs, though specific regions and timelines have yet to be disclosed. The recent funding of USD 4.

000 mn raised in November 2015 will be utilized to support these initiatives, enhancing their research and development capabilities and accelerating the pathway to market for their innovative therapies.